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Research and patient communities are firmly interdependent. Engaged patient 
communities provide biological samples and data that drive discoveries that, in turn, fuel 
the development of novel therapies.  Historically, Huntington's disease (HD) has 
benefited from trusting interactions between scientists and patients.  However, even for 
HD, communication between the research and patient communities is suboptimal.  The 
web platform HDBuzz was created to rectify this situation by providing accurate, 
accessible information on the latest HD research to patients and their supporters. 
 
The history 
The close relationship between patients and scientists developed from the begining of 
HD research and has greatly furthered studies into the mechanisms of the disease. The 
genetic locus for HD was mapped to chromosome 4 in 1983 in two families, one 
American and one Venezuelan [1], whose pedigrees were collected by two large-scale 
patient observation efforts - the National Research Roster for Huntington Disease 
Patients and Families at Indiana University and the Venezuela Collaborative HD Project.  
Continued investigation led to the cloning of the causative gene in 1993 [2].  Since 1993 
a number of large-scale observational projects have studied both symptomatic [3] and 
pre-symptomatic [4,5] mutation carriers.  Predictive testing has become widespread [6], 
and reproductive options for HD families now include pre-natal screening that can 
prevent transmission of the mutant allele [7]. 
 
The cloning of the HD gene led to great excitement in some quarters that disease-
modifying therapies would be forthcoming.  This excitement was tempered for others by 
the realization that the mutation occurred in a large (340 kDa) and highly-conserved, yet 
novel, protein [2].  Clearly, future therapies would need to rest on a broad foundation of 
understanding both the function of the protein itself as well as the mechanism by which 
the mutation causes pathology.  
 
In the intervening 18 years, knowledge of the precise genetic cause of HD has made the 
disease a fertile area for study.  In addition to clinical data, studies in a vast array of 
models of the disease, from yeast [8] to primates [9], generate hundreds of publications 
per year.  Many patients, encouraged by the speed of the remarkable series of 
experiments that led to the identification of the gene, have found the pace of subsequent 
progress from gene to effective treatments disappointing.   
 
The obstacles  
 
The HD community is extremely hungry for information about ongoing research, but any 
‘lay person’ motivated enough to penetrate the paywalls of journal websites or attend 
exclusive scientific conferences is confronted by even more daunting barriers of jargon 
and the assumption of years of prior formal study. Furthermore, the vast array of 
scientific results presents a problem to patients: as non-experts, how can they judge 
which advances are relevant to them? 
 
Another, more insidious, factor has contributed to patient disillusionment.  Aware of the 
importance of piquing public interest in sustaining funding, university-based research 
organizations have embraced the practice of public relations. Scientific research 
publications on topics related to human disease are frequently accompanied, or 
preceded, by a press release touting the potential cures promised by this new 
breakthrough.  These releases - often not written by non-scientists or 'enhanced' by 
press offices - have been said to "promote research that has uncertain relevance to 
human health" and fail to "provide key facts or acknowledge important limitations" [10].  
These press releases, having passed into the public domain, may then be magnified 
further by sensationalist media reporting. Famously, one British newspaper has been 
accused of seeking to dichotomize all known substances into those that can either cause 
or cure cancer (http://www.guardian.co.uk/commentisfree/2010/oct/16/ben-goldacre-
bad-science-daily-mail-cancer).  Speculative discussion in online communities such as 
blogs and discussion fora can have a multiplicative effect on the drawing of conclusions 
unwarranted by the primary research findings. 
 
There have been positive research developments for HD patients, but successfully 
testing these therapies will require a large pool of potential volunteers, particularly as the 
distribution of sites for any given trial is not homogenous and inclusion/exclusion criteria 
are strict.  There are now more trials for HD than ever before 
(http://clinicaltrials.gov/ct2/results?term=huntington%27s), providing hope that 
meaningful therapies may be available soon.  Recruitment for recent trials in HD has 
been disappointingly slow, but educating patients about HD drug trials appears to 
increase recruitment rates, supporting the hypothesis that a lack of reliable information is 
a major hurdle to successful trial recruitment [11]. 
 
HDBuzz: bridging the communication gap 
 
Inspired by discussions with young people affected by HD at a youth group meeting of 
the European Huntington Disease Network, we recently developed and launched 
'HDBuzz' (http://hdbuzz.net/) in an effort to help bridge this communication gap between 
the research and HD patient communities.  HDBuzz is an online information source for 
people affected by HD and the community of carers that surrounds them.  HDBuzz 
publishes short articles written in plain language that summarize recent clinical or basic 
research advances.  Each article is written by a clinician or scientist expert in the field, 
but one with no connection to the work being discussed.  Articles are signed by both the 
writer and editor, ensuring accountability for accuracy and legibility. Particular attention 
is given to placing each article within the context of the broader search for effective 
treatments, fostering a brand of realistic, pragmatic enthusiasm we refer to as 
'substantive hope'. 
 
All HDBuzz content is freely available under a Creative Commons license.  In addition to 
the web platform, content can be syndicated via RSS and javascript feeds, email, Twitter 
(@HDBuzzfeed) and Facebook (HDBuzzfeed). Because most HD families do not live in 
English speaking countries [12], HDBuzz is translated into other languages.  Thanks to a 
network of volunteer translators and a novel online interface, HDBuzz content is now 
available in Spanish, Portuguese, Italian, German, French, Polish, Danish and Dutch.   
 
To avoid potential conflicts of interest, HDBuzz does not accept funding from any 
organization with a stake in a specific therapy.  An international consortium of HD lay 
organizations provides funding to HDBuzz, with the understanding that it is completely 
independent editorially.  The founding partners of HDBuzz were the HD Association 
(England & Wales), Huntington Society of Canada and Huntington's Disease Society of 
America and since its launch, eight additional lay organizations have contributed towards 
its upkeep. This funding model provides maximum editorial independence for HDBuzz 
and removes even the appearance of bias towards any particular therapy. 
 
Many lay organizations, including the HD Association (England & Wales), Huntington 
Society of Canada and Huntington's Disease Society of America, use syndicated 
HDBuzz content to keep their communities informed about recent research news, 
freeing them to focus on the direct care they do best.  
 
Defining success 
 
HDBuzz is motivated by the idea that accurately communicating research to the affected 
community is a moral obligation of the scientific community: a work of science is not 
complete until this has been done.  Meeting this obligation is the primary goal of HDBuzz 
and will be judged by the increased understanding of the scientific process in affected 
communities. 
 
There are practical benefits of informed engagement for the entire HD community.  
Based on preliminary studies [11], it is hoped that careful education of HD families will 
lead to their more active participation in observational and clinical trials.  Parsing the 
specific effects of HDBuzz in this effort will be difficult, but the goal of this practical 
motivation is to reduce recruitment time for new clinical trials and to rapidly fill ongoing 
observational trials with engaged and motivated participants.  It is only by completing 
trials that we can close the circle of research and bring the fruits of basic and clinical 
science to patients.  
  
 
Results 
 
Since launching in January 2011, traffic to the site has rapidly increased to over 56,000 
visits a month, and more than 800 people have signed up to receive HDBuzz stories by 
email subscription (Figure 1; real-time statistics are available online at 
http://hdbuzz.net/statistics).  Given the relative rarity of HD [13], this represents 
penetration into a significant proportion of the HD patient community in a very short time. 
 
Through the web platform, users are encouraged to provide immediate feedback by 
clicking buttons labeled "Enjoyed" or "Didn't understand".  Qualitative feedback suggests 
the message of cautious optimism is being communicated, even when covering complex 
material.  In response to a recent story on genome editing, a reader commented, "great 
news and although a huge challenge its not impossible".  Simultaneously grasping the 
excitement of recent developments and the difficulties in implementing them is precisely 
our goal.  An article dealing with media reports reporting possible effects of cannabis 
and caffeine in HD prompted the comment “It clarifies many questions and also provide 
how we should interpret health news like this one”. 
  
 
Beyond HDBuzz 
 
The early success of HDBuzz suggests that there is a significant unmet hunger for 
accurate research news in the patient community, and it seems unlikely that this appetite 
is limited to families afflicted by Huntington's Disease.  Similar platforms, staffed by 
scientists with expertise in other clinical domains, may provide significant benefits to 
these areas.  Our experience, and the web-based tools we have developed, may be 
useful for these efforts. The hope is that HDBuzz can serve as a template for how to 
bridge the scientific communication gap with obvious benefits to researchers and 
patients alike. 
 
 
 
 
Figure Caption: Summary of email subscribers (orange) and daily article views (blue 
line, 5-day moving mean; dashed line, linear trend) at HDBuzz.net since launch on 
January 19, 2011. 
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